UBS AM
CYCN icon

UBS AM’s Cyclerion Therapeutics CYCN Stock Holding History

UBS AM’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-507
Closed -$11.3K – 2708
2022
Q1 		$11.3K Hold
507
– – ﹤0.01% 2776
2021
Q4 		$17.5K Hold
507
– – ﹤0.01% 2836
2021
Q3 		$31.2K Hold
507
– – ﹤0.01% 2737
2021
Q2 		$39.6K Hold
507
– – ﹤0.01% 2743
2021
Q1 		$28.3K Hold
507
– – ﹤0.01% 2597
2020
Q4 		$31.1K Sell
507
-724
-59% -$49.4K ﹤0.01% 2542
2020
Q3 		$150K Hold
1,231
– – ﹤0.01% 2437
2020
Q2 		$145K Sell
1,231
-2,217
-64% -$185K ﹤0.01% 2429
2020
Q1 		$183K Buy
3,448
+1,311
+61% +$93.5K ﹤0.01% 2297
2019
Q4 		$116K Sell
2,137
-49,882
-96% -$4.66M ﹤0.01% 2507
2019
Q3 		$12.6M Buy
52,019
+11,741
+29% +$2.54M 0.01% 882
2019
Q2 		$9.22M Buy
+40,278
New +$11.4M 0.01% 989

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UBS AM's CYCN Position: Q2 2022 in Review

UBS AM sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 507 shares — an estimated $11.3K sold.

UBS AM first reported a position in CYCN in Q2 2019 and held it in 12 quarters. The position peaked at $12.6M in Q3 2019. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • UBS AM reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 507 Cyclerion Therapeutics shares in Q2 2022, an estimated $11.3K.
  • UBS AM first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 12 quarters.
  • UBS AM's Cyclerion Therapeutics position peaked at $12.6M in Q3 2019.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.